116
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Significance of Stenotrophomonas maltophilia When Detected in Sputum of Ambulatory Patients with COPD

ORCID Icon, , , , & ORCID Icon
Pages 2895-2900 | Published online: 20 Oct 2021

References

  • Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999;14(5):1015–1022. doi:10.1183/09031936.99.14510159
  • Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2–41.
  • Nseir S, Di Pompeo C, Brisson H, et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care. 2006;10(5):R143. doi:10.1186/cc5063
  • Falissard B. Focused principal component analysis: looking at a correlation matrix with a particular interest in a given variable. J Comput Graph Stat. 1999;8(4):906–912.
  • Zhanel GG, Adam HJ, Baxter MR, et al. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 Study. J Antimicrob Chemother. 2013;68(Suppl 1):i7–22. doi:10.1093/jac/dkt022
  • Goncalves-Vidigal P, Grosse-Onnebrink J, Mellies U, Buer J, Rath PM, Steinmann J. Stenotrophomonas maltophilia in cystic fibrosis: improved detection by the use of selective agar and evaluation of antimicrobial resistance. J Cyst Fibros. 2011;10(6):422–427. doi:10.1016/j.jcf.2011.06.010
  • Brooke JS. New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther. 2014;12(1):1–4. doi:10.1586/14787210.2014.864553
  • Canadian cystic fibrosis registry. Annual data report. 2019.
  • Toro MDD, Rodríguez-Baño J, Herrero M, et al. Clinical epidemiology of stenotrophomonas maltophilia colonization and infection: a Multicenter Study. Medicine. 2002;81(3):228–239. doi:10.1097/00005792-200205000-00006
  • Ding X, Wu X, Peng Y, Hu S, Nie H. Risk factors of superinfection following imipenem/cilastatin therapy in hospitalised patients with acute exacerbations of severe chronic obstructive pulmonary disease. Int J Clin Pract. 2006;60(7):806–811. doi:10.1111/j.1742-1241.2006.00829.x
  • Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005. J Cyst Fibros. 2009;8(6):386–391. doi:10.1016/j.jcf.2009.08.003